The mitral valve has been an especially challenging target for transcatheter interventions, but there are reasons to think key breakthroughs are on the horizon. We talked to Kendra Grubb, MD, about this and other ongoing trends at TCT 2023. 

Kendra Grubb, MD, one of the country's leading experts on cardiac surgery, discussed what she tells her patients when they ask if TAVR is better than SAVR for treating severe aortic stenosis. 

More than 100 U.S. medical societies are throwing their support behind a new proposal that could reform out-of-date Medicare policies and help limit future payment cuts. 

IVUS was especially effective when treating patients with a complex coronary anatomy, researchers found. 

Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview. 

Short-term mortality, however, does not appear to change when TAVR patients present with active cancer. 

Intravascular lithotripsy therapy to break up calcified coronary lesions will now be reimbursed at a higher rate under new in-hospital codes the went into effect Oct. 1.

Robert Yeh, MD, detailed the importance of the pivotal AGENT IDE trial, which focused on the use of a paclitaxel-coated balloon to treat in-stent restenosis.